Retatrutide (GLP-1 + GIP + Glucagon) Retatrutide introduces a third mechanism: glucagon receptor agonism
Synthetic small-molecule oral GLP-1 receptor agonists are expected to be approved in 2026, while oral semaglutide is already available
Personalized Evaluation and Safety Considerations Before starting tirzepatide, the healthcare team at Centra Internal Medicine will conduct a thorough evaluation of your medical history, current medications, and overall health to ensure that this medication is safe and suitable for your specific needs
Vancampfort D, Mugisha J, Hallgren M, De Hert M, Probst M, Monsieur D, et al
Because they engage GH release through complementary, non-overlapping pathways, the combination is studied for synergistic GH elevation greater than either alone
The overall metabolic improvement may slow or halt the progressive dysfunction that characterizes untreated prediabetes